Kimberly-Clark to Acquire Kenvue in $40B Deal, Boosting Consumer Health Presence
Kimberly-Clark, a multinational personal care corporation, has initiated a thorough due diligence process with legal, health, and government experts to evaluate the acquisition of Kenvue, a consumer health company. The deal, valued at $40 billion, is expected to close in the second half of 2026, pending approval from shareholders and regulatory authorities.
Kimberly-Clark has valued Kenvue at $21.01 per share, a slight premium over its pre-announcement trading price. Talks between the two companies began after Kenvue announced a strategic review in July. The acquisition is seen as a bet by Kimberly-Clark on the market overreacting to recent events, such as the Trump administration's link between Tylenol and autism, which has potentially impacted Kenvue's health insurance valuation.
The deal, which involves Kimberly-Clark's shareholders and Kenvue's own shareholders, is expected to strengthen Kimberly-Clark's position in the consumer health market. Both companies have been transparent about the process, with Kimberly-Clark informing its shareholders before the completion of the deal.
Kimberly-Clark's acquisition of Kenvue, valued at $40 billion, is subject to shareholder and regulatory approval. The deal, influenced by market dynamics and recent events, is expected to close in late 2026, marking a significant expansion for Kimberly-Clark in the consumer health sector.
